Evidence map›Paper›PMID 38659023›Full record

ArticleEuropean journal of medical research2024

Competitive adsorption of microRNA-532-3p by circular RNA SOD2 activates Thioredoxin Interacting Protein/NLR family pyrin domain containing 3 pathway and promotes pyroptosis of non-alcoholic fatty hepatocytes.

FengJuan Chen, YuFeng Xing, ZhiJie Chen, XiaoMan Chen, Jie Li, Si Gong, Fang Luo, QingXian Cai

Open access · greenAbstract read
In one paragraph

Article in European journal of medical research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact, top 100% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 0 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

FengJuan Chen *Department of Hepatopathy, The Third People's Hospital of Shenzhen, The Second Affiliated Hospital of Southern University of Science and Technology, No. 29, Bulan Road, Longgang District, Shenzhen City, 518112, Guangdong Province, China.
YuFeng Xing *Department of Hepatopathy, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen City, 518033, Guangdong Province, China.
ZhiJie ChenDepartment of Hepatopathy, The Third People's Hospital of Shenzhen, The Second Affiliated Hospital of Southern University of Science and Technology, No. 29, Bulan Road, Longgang District, Shenzhen City, 518112, Guangdong Province, China.
XiaoMan ChenDepartment of Infectious Diseases, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou City, 510630, Guangdong Province, China.
Jie LiDepartment of Hepatopathy, The Third People's Hospital of Shenzhen, The Second Affiliated Hospital of Southern University of Science and Technology, No. 29, Bulan Road, Longgang District, Shenzhen City, 518112, Guangdong Province, China.
Si GongDepartment of Hepatopathy, The Third People's Hospital of Shenzhen, The Second Affiliated Hospital of Southern University of Science and Technology, No. 29, Bulan Road, Longgang District, Shenzhen City, 518112, Guangdong Province, China.
Fang LuoDepartment of Hepatopathy, The Third People's Hospital of Shenzhen, The Second Affiliated Hospital of Southern University of Science and Technology, No. 29, Bulan Road, Longgang District, Shenzhen City, 518112, Guangdong Province, China.
QingXian CaiDepartment of Hepatopathy, The Third People's Hospital of Shenzhen, The Second Affiliated Hospital of Southern University of Science and Technology, No. 29, Bulan Road, Longgang District, Shenzhen City, 518112, Guangdong Province, China. cqx200000@163.com.
Southern University of Science and Technology · CNShenzhen Pingle Orthopedic Hospital · CNSun Yat-sen University · CN

Funding

Sanming Project of Medicine in Shenzen Municipality SZSM201612014Shenzhen Fundamental Research Program JCYJ20210324130415040The funds for the construction of key medical disciplines in Shenzhen No.SZXK076
6 · The paper itself

Abstract

objectiveThere is a growing body of evidence indicating that pyroptosis, a programmed cell death mechanism, plays a crucial role in the exacerbation of inflammation and fibrosis in the pathogenesis of non-alcoholic fatty liver disease (NAFLD). Circular RNAs (circRNAs), functioning as vital regulators within NAFLD, have been shown to mediate the process of cell pyroptosis. This study aims to elucidate the roles and mechanisms of circRNAs in NAFLD.

methodsUtilizing a high-fat diet (HFD)-induced rat model for in vivo experimentation and hepatocytes treated with palmitic acid (PA) for in vitro models, we identified circular RNA SOD2 (circSOD2) as our circRNA of interest through analysis with the circMine database. The expression levels of associated genes and pyroptosis-related proteins were determined using quantitative real-time polymerase chain reaction and Western blotting, alongside immunohistochemistry. Serum liver function markers, cellular inflammatory cytokines, malondialdehyde, lactate dehydrogenase levels, and mitochondrial membrane potential, were assessed using enzyme-linked immunosorbent assay, standard assay kits, or JC-1 staining. Flow cytometry was employed to detect pyroptotic cells, and lipid deposition in liver tissues was observed via Oil Red O staining. The interactions between miR-532-3p/circSOD2 and miR-532-3p/Thioredoxin Interacting Protein (TXNIP) were validated through dual-luciferase reporter assays and RNA immunoprecipitation experiments.

resultsOur findings demonstrate that, in both in vivo and in vitro NAFLD models, there was an upregulation of circSOD2 and TXNIP, alongside a downregulation of miR-532-3p. Mechanistically, miR-532-3p directly bound to the 3'-UTR of TXNIP, thereby mediating inflammation and cell pyroptosis through targeting the TXNIP/NLR family pyrin domain containing 3 (NLRP3) inflammasome signaling pathway. circSOD2 directly interacted with miR-532-3p, relieving the suppression on the TXNIP/NLRP3 signaling pathway. Functionally, the knockdown of circSOD2 or TXNIP improved hepatocyte pyroptosis; the deletion of miR-532-3p reversed the effects of circSOD2 knockdown, and the deletion of TXNIP reversed the effects of circSOD2 overexpression. Furthermore, the knockdown of circSOD2 significantly mitigated the progression of NAFLD in vivo.

conclusioncircSOD2 competitively sponges miR-532-3p to activate the TXNIP/NLRP3 inflammasome signaling pathway, promoting pyroptosis in NAFLD.

Indexed as

Cell Cycle ProteinsHepatocytesMicroRNAsNLR Family, Pyrin Domain-Containing 3 ProteinNon-alcoholic Fatty Liver DiseasePyroptosisRNA, CircularAnimalsCarrier ProteinsDiet, High-FatDisease Models, AnimalHumansMaleRatsRats, Sprague-DawleySignal TransductionCarrier ProteinsCell Cycle ProteinsMicroRNAsMIRN532 microRNA, humanMIRN532 microRNA, ratNLR Family, Pyrin Domain-Containing 3 ProteinNlrp3 protein, ratRNA, CircularSuperoxide DismutaseSuperoxide Dismutase 2ThioredoxinsTXNIP protein, ratCircular RNA SOD2MicroRNA-532-3pNon-alcoholic fatty liver diseasePyroptosis

Identifiers

PMID38659023
PMCPMC11044449
OpenAlexW38659023

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.